Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ContraFect Corporation (NASDAQ: CFRX).

Full DD Report for CFRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CFRX)

ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia
YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that...
Source: GlobeNewswire
Date: September, 06 2018 08:30
ContraFect to Present at Two Upcoming Investor Conferences
YONKERS, N.Y., Aug. 29, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that ...
Source: GlobeNewswire
Date: August, 29 2018 17:30
ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
YONKERS, New York, Aug. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the p...
Source: GlobeNewswire
Date: August, 22 2018 17:00
ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections
YONKERS, N.Y., Aug. 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Ca...
Source: GlobeNewswire
Date: August, 14 2018 17:00
Contrafect Corporation: A Novel Antimicrobial Technology To Combat Hospital Acquired Infections
Introduction In this article, I will delve in-depth into Contrafect Corporation's (CFRX) recent publications into the use of their lead compound CF-301 to treat, disrupt, and kill bacteria in biofilms. I will describe why this is an important new use for CF-301 and how it can help many patie...
Source: SeekingAlpha
Date: August, 13 2018 11:40
ContraFect: Interesting Technology, Upcoming Catalyst, Cautious Outlook
ContraFect Corporation ( CFRX ) is a microcap company that has an important upcoming catalyst in the form of phase 2 data from its trial of CF-301 in serious infections caused by Staph aureus including MRSA. This is interesting because the company has licensed technology from the Rockefeller U...
Source: SeekingAlpha
Date: August, 13 2018 04:18
Contrafect reports Q2 results
Contrafect (NASDAQ: CFRX ): Q2 EPS of -$0.27 More news on: CONTRAFECT Corp, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 09 2018 07:19
ContraFect Announces Second Quarter 2018 Financial Results
YONKERS, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for t...
Source: GlobeNewswire
Date: August, 09 2018 07:00
ContraFect Corporation prices $10M equity offering
ContraFect Corporation ( CFRX -8.7% ) has priced its public offering of 5M common shares at $2.00 per share for gross proceeds of $10M. More news on: CONTRAFECT Corp, Read more ...
Source: SeekingAlpha
Date: July, 27 2018 09:33
Premarket Losers as of 9:05 am (7/27/2018)
TNXP   -77%  after PTSD study failed . More news on: Tonix Pharmaceuticals Holding Corp., American Midstream Partners, LP, Southcross Energy Partners, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: July, 27 2018 09:17

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-132.082.062.17062.023104,802
2018-12-122.052.052.131.99212,922
2018-12-112.122.04112.151.97122,984
2018-12-102.142.092.202.02259,639
2018-12-072.082.152.292.05337,658

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1311,36426,24843.2947Short
2018-12-1266,164104,98363.0235Short
2018-12-1191,203104,62587.1713Short
2018-12-1053,13989,11459.6304Short
2018-12-0764,113181,29135.3647Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CFRX.


About ContraFect Corporation (NASDAQ: CFRX)

Logo for ContraFect Corporation (NASDAQ: CFRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CFRX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 21 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: March, 21 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 15 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 15 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: CFRX)

      Daily Technical Chart for (NASDAQ: CFRX)


      Stay tuned for daily updates and more on (NASDAQ: CFRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CFRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CFRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CFRX and does not buy, sell, or trade any shares of CFRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/